News Category
Onco-Innovations' potential acquisition of an exclusive option on Ifowonco's oral LAG-3 inhibitor program could position the company at the forefront ...
Creative Biolabs has expanded its complement assay services, providing researchers with advanced tools to evaluate complement-targeted therapeutics an...
Quantum BioPharma's Lucid-MS targets myelin degradation, offering a novel approach to treating multiple sclerosis that may address disability progress...
Silo Pharma's receipt of a Canadian patent allowance for SPC-15 strengthens its global IP position and supports its strategy to develop a novel intran...
Quantum BioPharma's Lucid-MS, a novel myelin-protecting therapy for multiple sclerosis, gains FDA clearance for phase 2 trials, highlighting a shift t...
Regentis Biomaterials received a Japanese Notice of Allowance for its solvent-free manufacturing process, strengthening its IP portfolio and supportin...
VERAXA Biotech's collaboration with Ardigen uses AI to optimize its BiTAC platform, potentially reducing development risks and reviving abandoned drug...
VERAXA Biotech's collaboration with Ardigen uses AI to optimize dual-target cancer therapies, potentially reviving abandoned drug targets and improvin...
The American Heart Association is accepting applications for its 2026 Health Tech Competition, aiming to bridge the gap between promising health techn...
Researchers have identified a protein on glioblastoma cells that could be targeted to make the cancer more vulnerable to existing treatments, offering...
NanoViricides is set to begin a Phase II clinical trial of its oral antiviral NV-387 for Ebola in the Democratic Republic of Congo, potentially offeri...
Helus Pharma appoints Regina Donohue as Chief People Officer and Suresh Durgam to its Scientific Advisory Board, signaling strategic preparation for c...
Cayenne Wellness Center's 20th Annual Sickle Cell Disease Educational Summit, themed '20/20 Vision: Our Legacy Continues,' highlights two decades of p...
Helix BioPharma has appointed Dr. Markus Loeffler as Chief Medical Officer to lead its clinical programs, including a planned Phase Ib/II trial of L-D...
Quantum BioPharma's significant cost reduction and FDA approval for its Phase 2 trial of Lucid-MS for progressive multiple sclerosis underscore its st...
Regentis Biomaterials is progressing its GelrinC cartilage repair product through U.S. pivotal trials and European commercialization simultaneously, w...
Alpha Cognition's Q2 2026 results show accelerating demand for ZUNVEYL, with revenue up 71% sequentially and strong prescription growth, positioning t...
The Lung Cancer Foundation of America and the International Association for the Study of Lung Cancer have awarded $200,000 each to two early-career sc...
PX1 Research's domestic cGMP-certified manufacturing and seven-stage testing protocol now ensure 99%+ purity for research peptides, offering batch-lev...
A comprehensive review in World Journal of Pediatric Surgery synthesizes current operative strategies for necrotizing enterocolitis, emphasizing bowel...
Onco-Innovations is progressing its precision oncology program ONC010, a nanoparticle-encapsulated PNKP inhibitor, through key manufacturing and metab...
Regentis Biomaterials' GelrinC, a cell-free hydrogel implant for knee cartilage repair, gains European approval for a more efficient manufacturing pro...
A study from the University of Manchester reveals that a previously underappreciated group of immune cells is essential for mobilizing and sustaining ...
Quantum BioPharma reports a 53% reduction in Q2 operating expenses and FDA approval to proceed with Phase 2 trials for Lucid-MS in progressive multipl...
Regentis Biomaterials is concurrently progressing its GelrinC cartilage repair implant through US Phase III trials and European commercialization, wit...
Lantern Pharma reports Q2 2026 results, highlighting progress in its AI-driven oncology pipeline and the establishment of Open Medicine AI as a separa...
Helus Pharma reported completion of enrollment in its pivotal Phase 3 APPROACH trial for HLP003 in major depressive disorder, with topline data expect...
DM Clinical Research marks its 20th anniversary, highlighting its growth into a leading network with over 35 sites and 35,000 enrolled patients, under...
NeOnc Technologies' NEO100 shows promising Phase 2a results, with significant survival benefits and regulatory momentum, positioning the company for p...
PX1 Research's new batches of Retatrutide and Tirzepatide peptides, manufactured under cGMP standards with rigorous HPLC verification, provide researc...
Quantum BioPharma is advancing a myelin-focused candidate, Lucid-MS, to address progression independent of relapse activity, a key driver of long-term...
GeoVax highlights its MVA-based vaccine candidates and expertise as the Bundibugyo Ebola outbreak in Congo becomes the fastest-growing on record, posi...
Dozens of global drugmakers are investing approximately $500 billion in the U.S. to avoid planned tariffs on drug imports, potentially reshaping the p...
Nutriband's CEO will showcase its AVERSA abuse-deterrent transdermal technology at a major industry summit, underscoring its potential to combat opioi...
Quantum BioPharma's FDA clearance to advance Lucid-MS into Phase 2 trials marks a significant step toward a potential neuroprotective therapy for mult...
PX1 Research introduces a domestically manufactured line of sublingual peptide strips for non-invasive research applications, potentially reshaping ho...
PX1 Research has expanded its US-based manufacturing to include seven-stage HPLC purity verification ensuring 99%+ purity on all research peptides, pr...
NanoViricides' regulatory approval to test its oral antiviral NV-387 in a Phase II Ebola trial in the DRC marks a potential shift toward more accessib...
New research from the University of Virginia suggests focused ultrasound could enhance drug delivery to gliomas, offering a less harmful alternative t...
Telomir Pharmaceuticals announced peer-reviewed preclinical data showing Telomir-Zn suppresses tumor growth in prostate and triple-negative breast can...
Quantum BioPharma's FDA approval to advance Lucid-MS into Phase 2 trials marks a pivotal step toward a potential neuroprotective therapy for multiple ...
Tonix Pharmaceuticals' second-quarter revenue surged to $13.5 million, driven by TONMYA's $11 million in net sales, marking a significant commercial m...
Tonix Pharmaceuticals' Q2 2026 revenue surged to $13.5 million, driven by TONMYA's $11 million in sales, marking a significant commercial milestone an...
Tonix Pharmaceuticals' strong Q2 2026 revenue, driven by TONMYA sales, underscores its commercial progress and financial stability, positioning it for...
A new narrative review in the World Journal of Pediatric Surgery provides a comprehensive framework for risk-adapted management of neuroblastoma, emph...
Regentis Biomaterials is progressing its GelrinC cartilage regeneration technology through clinical trials, regulatory submissions, and European comme...
Quantum BioPharma advances a two-pronged approach to neurological health, with Lucid-MS for multiple sclerosis and unbuzzd for alcohol misuse, highlig...
Quantum BioPharma advances a two-pronged approach to neurological health, combining its investigational MS therapy Lucid-MS with its supplement unbuzz...
